{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Group+C+-+Placebo",
    "query": {
      "intervention": "Group C - Placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 471,
    "total_pages": 48,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Group+C+-+Placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T11:05:24.364Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01967940",
      "title": "Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "HIV Infections",
        "Acquired Immunodeficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Current failing ARV regimen",
          "type": "DRUG"
        },
        {
          "name": "ATV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2013-10-25",
      "completion_date": "2017-07-31",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 5,
      "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Wilton Manors",
          "state": "Florida"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01967940"
    },
    {
      "nct_id": "NCT03030248",
      "title": "Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile Infection",
        "Hematologic Diseases",
        "Bone Marrow Transplant",
        "Oncologic Disorders"
      ],
      "interventions": [
        {
          "name": "Vancomycin Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2018-06-01",
      "completion_date": "2020-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03030248"
    },
    {
      "nct_id": "NCT06879067",
      "title": "Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety",
        "Tolerability"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Foralumab Nasal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tiziana Life Sciences LTD",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2018-11-12",
      "completion_date": "2020-11-09",
      "has_results": false,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06879067"
    },
    {
      "nct_id": "NCT01236040",
      "title": "Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals' investigational vaccine GSK2590066A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational vaccine GSK2592984A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational vaccine GSK2340274A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational vaccine GSK2340273A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 521,
      "start_date": "2010-11-29",
      "completion_date": "2012-08-20",
      "has_results": false,
      "last_update_posted_date": "2017-05-10",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01236040"
    },
    {
      "nct_id": "NCT07675629",
      "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhydrogel adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Vaccines, Protein Vaccines and Adjuvants",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Worcester HIV Vaccine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 126,
      "start_date": "2026-09-01",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07675629"
    },
    {
      "nct_id": "NCT05332717",
      "title": "TKA Melatonin and Sleep Quality",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Arthroplasty",
        "Replacement",
        "Knee",
        "Sleep Initiation and Maintenance Disorders"
      ],
      "interventions": [
        {
          "name": "Melatonin 5 mg",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo (Vitamin C)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2022-01-10",
      "completion_date": "2022-04-30",
      "has_results": false,
      "last_update_posted_date": "2023-09-14",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05332717"
    },
    {
      "nct_id": "NCT01038739",
      "title": "Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diverticulitis"
      ],
      "interventions": [
        {
          "name": "Mesalazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. Falk Pharma GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 330,
      "start_date": "2010-01",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-21",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 1,
      "location_summary": "New Smyrna Beach, Florida",
      "locations": [
        {
          "city": "New Smyrna Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01038739"
    },
    {
      "nct_id": "NCT02718495",
      "title": "Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "PTI-428",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Proteostasis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2016-07-19",
      "completion_date": "2017-11-28",
      "has_results": false,
      "last_update_posted_date": "2019-03-21",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 20,
      "location_summary": "Stanford, California • Altamonte Springs, Florida • Gainesville, Florida + 16 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02718495"
    },
    {
      "nct_id": "NCT02839330",
      "title": "A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Avian Influenza"
      ],
      "interventions": [
        {
          "name": "aH5N1c",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3196,
      "start_date": "2016-07-11",
      "completion_date": "2017-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 26,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02839330"
    },
    {
      "nct_id": "NCT02925442",
      "title": "Genicular Radiofrequency Ablation for Unilateral Knee Arthroplasty Pain Management",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "t-RFA",
          "type": "PROCEDURE"
        },
        {
          "name": "C-RFA",
          "type": "PROCEDURE"
        },
        {
          "name": "Control",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Lyman Medical Research Foundation, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2017-01-25",
      "completion_date": "2020-02-07",
      "has_results": false,
      "last_update_posted_date": "2019-05-24",
      "last_synced_at": "2026-09-12T11:05:24.364Z",
      "location_count": 2,
      "location_summary": "Coeur d'Alene, Idaho • Spokane, Washington",
      "locations": [
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02925442"
    }
  ]
}